Innate Pharma Reports Q3 2025 Business Update and Financial Results: Lacutamab Advancing Toward Phase 3 Initiation, IPH4502 Nectin-4 ADC Progressing Well, and Monalizumab PACIFIC-9 on Track for H2 2026 Data

Innate Pharma reported its Q3 2025 business update and financial results. Lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome, following FDA clearance for a confirmatory Phase 3 trial. IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well, with a pharmacologically active dose reached. Monalizumab PACIFIC-9 is on track to deliver data in H2 2026. The company has a cash position of €56.4 million as of September 30, 2025, and anticipates a cash runway until end Q3-2026.